医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NanoVibronix Announces Webinar Series to Promote UroShield

2022年07月12日 PM09:30
このエントリーをはてなブックマークに追加


 

ELMSFORD, N.Y.

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its Australian distributor, DukeHill HC, is launching a series of educational webinars to present the Company’s UroShield technology to clinicians. The series, which will feature clinicians and patients’ experiences, seeks to inform clinicians about the use, benefits and outcomes achieved when using the Company’s device.

“This webinar series is designed to increase awareness of UroShield and drive increased sales through our Australian distribution partner, DukeHill HC,” stated Brian Murphy, CEO of NanoVibronix, Inc. “Over the course of three, one-hour webinars, our technology will be introduced to hundreds of clinicians. Clinicians can gain valuable insight into our UroShield device by learning how it is used and the patients who can benefit from its use. Participants will have an opportunity to ask questions, and each webinar will feature case studies and testimonials from patients who have been treated with the device.”

Murphy added, “Subsequent to the webinar series, DukeHill will be launching a social media campaign to supplement the marketing efforts and further increase product and brand awareness.”

The first webinar is scheduled for July 21, 2022. Subsequent sessions are scheduled for August 4 and 18, 2022. For additional information, please visit DukeHill Webinar Promo – YouTube.

The webinars will be recorded and made available for replay on the Company’s website at: https://www.nanovibronix.com.

About DukeHill HC

DukeHill HC is a leader in advancing clinical education and has a high level of clinical and technical expertise with a strong focus on meeting the changing healthcare requirements in Australia. DukeHill HC’s purpose is to address the needs of healthcare professionals with the supply of quality, cost effective, minimally invasive, and consumable devices which will enable clinicians to obtain best practice outcomes for their patients.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed, (ii) market acceptance of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv) inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much larger, multinational companies; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005143/en/

CONTACT

Investor Contacts:

Brett Maas, Managing Principal, Hayden IR, LLC

brett@haydenir.com

(646) 536-7331

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer
  • エクセンシアの2022年第2四半期および上半期ビジネスアップデート
  • Exscientia通报2022年二季度和上半年业务进展
  • European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
  • Aurion Biotech Nominated for Prix Galien Startup Award